(CercleFinance.com) – Innate Pharma and Sanofi announce that Sanofi has exercised its licensing option for an NK Cell Engager program in solid tumors, originating from Innate’s ANKET platform, in accordance with the terms of the licensing agreement concluded in December 2022.
After a period of research collaboration, Sanofi will be responsible for product development, manufacturing and marketing. It retains a licensing option for an additional ANKET target in accordance with the agreement.
Innate will receive a payment of 15 million euros for the exercise of this option. It is eligible for milestone payments linked to the achievement of objectives, as well as royalties on potential net sales of up to 1.35 billion euros.